Discovery and Development of Telaprevir

[1]  R. Purcell,et al.  The hepatitis C virus: Overview , 1997, Hepatology.

[2]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[3]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[4]  Jean-Michel Pawlotsky,et al.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. , 2009, The New England journal of medicine.

[5]  S. Harbeson,et al.  Stereospecific synthesis of peptidyl alpha-keto amides as inhibitors of calpain. , 1994, Journal of medicinal chemistry.

[6]  T. Asselah,et al.  Protease and polymerase inhibitors for the treatment of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[7]  S. Raybuck,et al.  Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping. , 1997, Biochemistry.

[8]  H. Parge,et al.  The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.

[9]  M. Murcko,et al.  Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.

[10]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[11]  B. G. Rao,et al.  Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants. , 2003, Bioorganic & medicinal chemistry letters.

[12]  N. Cammack,et al.  Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors. , 2005, Virology.

[13]  John R Fulghum,et al.  In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 , 2004, Journal of Biological Chemistry.

[14]  J. Timm,et al.  Serine protease inhibitors as anti-hepatitis C virus agents , 2009, Expert review of anti-infective therapy.

[15]  Tara L. Kieffer,et al.  Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C , 2007, Hepatology.

[16]  B. G. Rao,et al.  Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization. , 2004, Bioorganic & medicinal chemistry letters.

[17]  Tara L. Kieffer,et al.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. , 2008, The Journal of infectious diseases.

[18]  Ann D. Kwong,et al.  VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[19]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[20]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[21]  M. Onji,et al.  Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Hassanein,et al.  Hepatitis C virus: a critical appraisal of approaches to therapy. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  F. Penin,et al.  Membrane Association of the RNA-Dependent RNA Polymerase Is Essential for Hepatitis C Virus RNA Replication , 2004, Journal of Virology.

[24]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[25]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[26]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[27]  I. Ugi,et al.  Multicomponent Reactions with Isocyanides. , 2000, Angewandte Chemie.

[28]  F. López-Labrador.  Hepatitis C Virus NS3/4A Protease Inhibitors. , 2008, Recent Patents on Anti-Infective Drug Discovery.

[29]  P. Jansen,et al.  New developments in the antiviral treatment of hepatitis C , 2009, Vox sanguinis.

[30]  I. Jacobson,et al.  New and experimental therapies for HCV , 2009, Nature Reviews Gastroenterology &Hepatology.

[31]  I. Weisberg,et al.  Telaprevir: hope on the horizon, getting closer. , 2009, Clinics in liver disease.

[32]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[33]  J. Glass,et al.  Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor. , 2004, Bioorganic & medicinal chemistry letters.

[34]  C. Rice,et al.  A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro , 1995, Journal of virology.

[35]  T. Berg,et al.  Expert opinion on the treatment of patients with chronic hepatitis C , 2009, Journal of viral hepatitis.

[36]  B. Kronenberger,et al.  Current and future treatment options for HCV. , 2009, Annals of hepatology.

[37]  A. Kwong,et al.  Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.

[38]  J. Macías,et al.  A review of current anti-HCV treatment regimens and possible future strategies , 2009, Expert opinion on pharmacotherapy.

[39]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[40]  A. Kwong,et al.  In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061* , 2005, Journal of Biological Chemistry.

[41]  R. Francesco,et al.  An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A , 1995, Journal of virology.

[42]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[43]  M. Murcko,et al.  Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants. , 2004, Bioorganic & medicinal chemistry letters.

[44]  K. Shimotohno,et al.  Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing , 1995, Journal of virology.

[45]  V. Soriano,et al.  New therapies for hepatitis C virus infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  C. Rice,et al.  The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[48]  R. Francesco,et al.  Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins , 1994, Journal of virology.

[49]  J. McHutchison,et al.  Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. , 2008, Journal of hepatology.

[50]  R. Bartenschlager,et al.  Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation , 1995, Journal of virology.

[51]  A. Urbani,et al.  A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. , 1996, Analytical biochemistry.

[52]  S. Zeuzem,et al.  Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. , 2006, Gastroenterology.

[53]  G. Castaldo,et al.  Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. , 2009, Current medicinal chemistry.

[54]  J. Monn,et al.  A Concise, Stereocontrolled Thiazolium Ylide Approach to Kainic Acid , 1994 .

[55]  A. Kwong,et al.  Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. , 2008, Current opinion in pharmacology.

[56]  A. Kwong,et al.  Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex. , 1998, Biochemistry.

[57]  A. Kwong,et al.  Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. , 2006, Infectious disorders drug targets.

[58]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[59]  A. Salonen,et al.  Viral RNA Replication in Association with Cellular Membranes , 2005, Current topics in microbiology and immunology.

[60]  D. Fairlie,et al.  Protease inhibitors: current status and future prospects. , 2000, Journal of medicinal chemistry.

[61]  S. Kanemasa,et al.  Highly diastereoselective Michael addition of lithiated camphor imines of glycine esters to α,β-unsaturated esters. Synthesis of optically pure 5-oxo-2,4-pyrrolidinedicarboxylates of unnatural stereochemistry , 1991 .